HC Wainwright Reiterates $34.00 Price Target for Stemline Therapeutics Inc (STML)
Stemline Therapeutics Inc (NASDAQ:STML) has been given a $34.00 target price by equities researchers at HC Wainwright in a research report issued to clients and investors on Monday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 300.00% from the stock’s current price.
A number of other equities analysts have also recently issued reports on the company. Zacks Investment Research cut Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 18th. Wedbush restated an “outperform” rating and set a $15.00 price target on shares of Stemline Therapeutics in a report on Tuesday, December 6th. Cowen and Company restated a “buy” rating on shares of Stemline Therapeutics in a report on Thursday, February 2nd. Ladenburg Thalmann Financial Services restated a “buy” rating on shares of Stemline Therapeutics in a report on Monday, February 6th. Finally, Jefferies Group LLC set a $16.00 price target on Stemline Therapeutics and gave the stock a “buy” rating in a report on Friday, February 3rd. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Stemline Therapeutics has a consensus rating of “Buy” and a consensus price target of $24.33.
Shares of Stemline Therapeutics (NASDAQ:STML) traded up 1.76% during trading on Monday, hitting $8.65. The stock had a trading volume of 100,430 shares. The firm has a 50 day moving average price of $7.79 and a 200-day moving average price of $10.60. Stemline Therapeutics has a 52 week low of $4.06 and a 52 week high of $14.60. The stock’s market capitalization is $155.28 million.
In other news, CEO Ivan Bergstein sold 17,980 shares of the company’s stock in a transaction that occurred on Tuesday, February 28th. The stock was sold at an average price of $6.99, for a total transaction of $125,680.20. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Kenneth Hoberman sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, February 27th. The stock was sold at an average price of $6.97, for a total value of $27,880.00. The disclosure for this sale can be found here. Insiders have sold 65,356 shares of company stock worth $531,879 over the last ninety days. 16.70% of the stock is owned by insiders.
Institutional investors have recently modified their holdings of the company. Perceptive Advisors LLC purchased a new position in shares of Stemline Therapeutics during the fourth quarter worth $115,000. Ladenburg Thalmann Financial Services Inc. raised its position in shares of Stemline Therapeutics by 810.6% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,694 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 11,300 shares during the last quarter. Oak Ridge Investments LLC raised its position in shares of Stemline Therapeutics by 26.3% in the third quarter. Oak Ridge Investments LLC now owns 12,796 shares of the biopharmaceutical company’s stock worth $139,000 after buying an additional 2,663 shares during the last quarter. State Treasurer State of Michigan purchased a new position in shares of Stemline Therapeutics during the third quarter worth $217,000. Finally, Acadian Asset Management LLC purchased a new position in shares of Stemline Therapeutics during the third quarter worth $400,000. 37.76% of the stock is currently owned by institutional investors.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.